Addressing prior-data conflict with empirical meta-analytic-predictive priors in clinical studies with historical information.

Abstract:

:A common question in clinical studies is how to use historical data from earlier studies, leveraging relevant information into the design and analysis of a new study. Bayesian approaches are particularly well-suited to this task, with their natural ability to borrow strength across data sources. In this paper, we propose an eMAP approach for incorporating historical data into the analysis of clinical studies, and we discuss an application of this method to the analysis of observational safety studies for a class of products for patients with hemophilia A. The eMAP prior approach is flexible and robust to prior-data conflict. We conducted simulations to compare the frequentist operating characteristics of three approaches under different prior-data conflict assumptions and sample size scenarios.

journal_name

J Biopharm Stat

authors

Li JX,Chen WC,Scott JA

doi

10.1080/10543406.2016.1226324

subject

Has Abstract

pub_date

2016-01-01 00:00:00

pages

1056-1066

issue

6

eissn

1054-3406

issn

1520-5711

journal_volume

26

pub_type

杂志文章
  • A global model to define the behavior of partial agonists (bell-shaped dose-response inducers) in pharmacological evaluation of activity in the presence of the full agonist.

    abstract::The dose-response models for full agonists and for a particular type of partial agonist can be described by sigmoidal curves and bell-shaped curves, respectively. The methods currently used to evaluate the interaction of a full agonist and a partial agonist require a large number of experimental units and base their a...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543409808835266

    authors: Ghosh K,Shen ES,Arey BJ,López FJ

    更新日期:1998-11-01 00:00:00

  • Exact inference for complex clustered data using within-cluster resampling.

    abstract::This paper introduces exact permutation methods for use when there are independent clusters of data with arbitrary within-cluster correlation. To eliminate the problem of clustering, we randomly select a data point from each cluster and for this now independent data, and calculate our test statistic and the associated...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543401003618884

    authors: Follmann D,Fay M

    更新日期:2010-07-01 00:00:00

  • Statistical innovations in the medical device world sparked by the FDA.

    abstract::The world of medical devices while highly diverse is extremely innovative, and this facilitates the adoption of innovative statistical techniques. Statisticians in the Center for Devices and Radiological Health (CDRH) at the Food and Drug Administration (FDA) have provided leadership in implementing statistical innova...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章,评审

    doi:10.1080/10543406.2015.1092037

    authors: Campbell G,Yue LQ

    更新日期:2016-01-01 00:00:00

  • Estimation of the combined response to treatment in multicenter trials.

    abstract::Analyses of multicenter trials consider the estimated treatment effect differences of the individual centers and combine them into an estimate of the overall treatment effect. There has been much debate in the literature concerning the best way to combine these treatment effect differences. We emphasize that first of ...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:

    authors: Dragalin V,Fedorov V,Jones B,Rockhold F

    更新日期:2001-11-01 00:00:00

  • Mixed-effects varying-coefficient model with skewed distribution coupled with cause-specific varying-coefficient hazard model with random-effects for longitudinal-competing risks data analysis.

    abstract::It is well known that there is strong relationship between HIV viral load and CD4 cell counts in AIDS studies. However, the relationship between them changes during the course of treatment and may vary among individuals. During treatments, some individuals may experience terminal events such as death. Because the term...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2015.1052493

    authors: Lu T,Wang M,Liu G,Dong GH,Qian F

    更新日期:2016-01-01 00:00:00

  • Etrank: a ranking procedure for handling missing data in clinical trials: application to venlafaxine extended-release depression clinical trial.

    abstract::ETRANK is a statistical software which uses nonparametric (randomization) technique to analyze incomplete repeated measures data, where the pattern of withdrawal is treatment related. This stand alone program is written in C, presently runs in MS-DOS, and a Windows version is in development. The program has been devel...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章,评审

    doi:10.1080/10543409608835156

    authors: Entsuah R

    更新日期:1996-11-01 00:00:00

  • Robust small-sample inference for fixed effects in general Gaussian linear models.

    abstract::Although asymptotically, the empirical covariance estimator is consistent and robust with respect to the selection of the working correlation matrix, when the sample size is small, its bias may not be negligible. This article proposes a small sample correction for the empirical covariance estimator in general Gaussian...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2011.557792

    authors: Fan C,Zhang D,Zhang CH

    更新日期:2012-01-01 00:00:00

  • On sample size determination in multi-armed confirmatory adaptive designs.

    abstract::An important application of confirmatory adaptive designs is the data-driven selection of treatment arms in multi-armed trials. A general methodology for adaptive designs is based on the combination testing principle. Using this principle, selection of treatment arms in multi-armed designs, recalculation of sample siz...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2011.551336

    authors: Wassmer G

    更新日期:2011-07-01 00:00:00

  • Influence Analysis for the Area Under the Receiver Operating Characteristic Curve.

    abstract::Classification measures play essential roles in the assessment and construction of classifiers. Hence, determining how to prevent these measures from being affected by individual observations has become an important problem. In this paper, we propose several indexes based on the influence function and the concept of l...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2017.1377728

    authors: Ke BS,Chiang AJ,Chang YI

    更新日期:2018-01-01 00:00:00

  • Clinical development and trial design of biosimilar products: a Japanese perspective.

    abstract::In recent years, development of biosimilar products has attracted considerable attention. Because of the structural complexity of biologics, it is difficult to demonstrate that a biosimilar product is identical to the reference product. Therefore, for the development of biosimilar products, we need to adopt an approac...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2014.941983

    authors: Nagasaki M,Ando Y

    更新日期:2014-01-01 00:00:00

  • A useful testing strategy in phase III trials: combined test of superiority and test of equivalence.

    abstract::A useful testing strategy is proposed for a confirmatory phase III clinical trial. It consists of a combined test of superiority and test of equivalence, and it is easy to apply. By introducing the strategy, we can perform a post hoc analysis in a confirmatory experiment. Thus a more flexible decision will be possible...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543409508835115

    authors: Morikawa T,Yoshida M

    更新日期:1995-11-01 00:00:00

  • Statistical design of noninferiority multiple region clinical trials to assess global and consistent treatment effects.

    abstract::Noninferiority multiregional clinical trials (MRCTs) have recently received increasing attention in drug development. While a major goal in an MRCT is to estimate the global treatment effect, it is also important to assess the consistency of treatment effects across multiple regions. In this paper, we propose an intui...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2017.1293075

    authors: Diao G,Zeng D,Ibrahim JG,Rong A,Lee O,Zhang K,Chen Q

    更新日期:2017-01-01 00:00:00

  • Estimating vaccine efficacy from outbreak size household data in the presence of heterogeneous transmission probabilities.

    abstract::We develop a Bayesian approach for estimating vaccine efficacy for susceptibility (VEs) and infectiousness (VEI) using outbreak size household data. Our method allows for heterogeneity in transmission probabilities due to factors that are related to individuals' characteristics, such as age, in addition to vaccination...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543400600719467

    authors: Davis XM,Waller LA,Haber M

    更新日期:2006-01-01 00:00:00

  • Statistical Properties of the Design for Simultaneous Global Drug Development Program.

    abstract::Recently, a design was proposed for the Simultaneous Global Drug Development Program (SGDDP) to assess the impact of ethnic factors on the effect of a new treatment for a targeted ethnic (TE) population. It used weighted Z tests to combine the information collected from the TE and non-TE (NTE) subgroups in the SGDDP b...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2014.971166

    authors: Liu K,Yuan Z,Chen G,Huang Q,Wenrich J

    更新日期:2015-01-01 00:00:00

  • Joint bent-cable Tobit models for longitudinal and time-to-event data.

    abstract::In this article, we show how to estimate a transition period for the evolvement of drug resistance to antiretroviral (ARV) drug or other related treatments in the framework of developing a Bayesian method for jointly analyzing time-to-event and longitudinal data. For HIV/AIDS longitudinal data, developmental trajector...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2017.1321006

    authors: Dagne GA

    更新日期:2018-01-01 00:00:00

  • Survival analysis and prognosis for dementia patients.

    abstract::How long a dementia patient is cared for in the home before admission to a nursing home depends on the state of the patient and the state of the caregiver. Using 5-year follow-up data, the times until entry to nursing home and until death are modeled using a Cox survival model in which patient and caregiver variables ...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543409408835076

    authors: McGilchrist CA,Brodaty H,Peters KE,Harris L

    更新日期:1994-03-01 00:00:00

  • A bias correction in testing treatment efficacy under informative dropout in clinical trials.

    abstract::In clinical trials of drug development, patients are often followed for a certain period of time, and the outcome variables are measured at scheduled time intervals. The main interest of the trial is the treatment efficacy at a prespecified time point, which is often the last visit. In such trials, patient dropout is ...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543400903242753

    authors: Kong F,Chen YF,Jin K

    更新日期:2009-11-01 00:00:00

  • Intent-to-randomize corrections for missing data resulting from run-in selection bias in clinical trials for chronic conditions.

    abstract::In many clinical trials for chronic conditions a run-in period is used prior to randomization. Often, only those participants who meet certain criteria during the run-in phase go on to get randomized. The others, along with the information that they might have provided, are excluded from the study. This exclusion of t...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2011.550107

    authors: Berger VW,Vali B

    更新日期:2011-03-01 00:00:00

  • Dunnett's many-to-one test and least square means.

    abstract::Dunnett's many-to-one test is used frequently today, especially in dose-finding studies. Using Dunnett's test, the Type I error level for the comparison between the raw mean of the control and the raw means of the study drug groups can be exactly calculated for the normal data. However, this computability depends on t...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1081/BIP-120017723

    authors: Shun Z,Silverberg A,Chang CK,Ouyang P

    更新日期:2003-02-01 00:00:00

  • A simulation study of approaches for handling disease progression in dose-finding clinical trials.

    abstract::In traditional dose-finding studies, dose-limiting toxicity (DLT) is determined within a fixed time observation window where DLT is often defined as a binary outcome. In the setting of oncology dose-finding trials, often patients in advanced stage of diseases are enrolled. Therefore, disease progression may occur with...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2020.1814796

    authors: Biard L,Cheng B,Manji GA,Lee SM

    更新日期:2020-09-15 00:00:00

  • Comparison of concordance correlation coefficient and coefficient of individual agreement in assessing agreement.

    abstract::In method comparison and reliability studies, it is often important to assess agreement between multiple measurements made by different methods, devices, laboratories, observers, or instruments. For continuous data, the concordance correlation coefficient (CCC) is a popular index for assessing agreement between multip...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543400701329497

    authors: Barnhart HX,Lokhnygina Y,Kosinski AS,Haber M

    更新日期:2007-01-01 00:00:00

  • A summary statistic for measuring change from baseline.

    abstract::A statistic, W, for measuring change from baseline is developed. Its distribution is found. Simulations using W and analysis of covariance (ANCOVA) are run and the results are compared. W is found to be less powerful than ANCOVA, yet is not seen to suffer some of the ill effects to which ANCOVA can fall prey, namely b...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543409708835187

    authors: Donahue RM

    更新日期:1997-05-01 00:00:00

  • Mixture-based gatekeeping procedures in adaptive clinical trials.

    abstract::Clinical trials with data-driven decision rules often pursue multiple clinical objectives such as the evaluation of several endpoints or several doses of an experimental treatment. These complex analysis strategies give rise to "multivariate" multiplicity problems with several components or sources of multiplicity. A ...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2017.1399901

    authors: Kordzakhia G,Dmitrienko A,Ishida E

    更新日期:2018-01-01 00:00:00

  • Modeling sustained treatment effects in tumor xenograft experiments.

    abstract::In cancer drug development, demonstrated efficacy in tumor xenograft models is an important step toward bringing a promising compound to human use. A key outcome variable is tumor volume measured over a period of time, while mice are treated with certain treatment regimens. A constrained parametric model has been prop...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2014.901340

    authors: Fang HB,Deng D,Zhang T,Tan M

    更新日期:2014-01-01 00:00:00

  • Evaluating methods for classifying expression data.

    abstract::An attractive application of expression technologies is to predict drug efficacy or safety using expression data of biomarkers. To evaluate the performance of various classification methods for building predictive models, we applied these methods on six expression datasets. These datasets were from studies using micro...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1081/BIP-200035491

    authors: Man MZ,Dyson G,Johnson K,Liao B

    更新日期:2004-11-01 00:00:00

  • A predictive risk probability approach for microarray data with survival as an endpoint.

    abstract::Gene expression profiling has played an important role in cancer risk classification and has shown promising results. Since gene expression profiling often involves determination of a set of top rank genes for analysis, it is important to evaluate how modeling performance varies with the number of selected top ranked ...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543400802277967

    authors: Chen DT,Schell MJ,Chen JJ,Fulp WJ,Eschrich S,Yeatman T

    更新日期:2008-01-01 00:00:00

  • Permutation test following covariate-adaptive randomization in randomized controlled trials.

    abstract::In randomized controlled trials, patients are recruited and randomly allocated to treatments. Patients are never randomly sampled from large population of patients on treatments under study. Therefore, it is important to consider the design and statistical analysis based on the randomization model. In this article, we...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543400802527908

    authors: Hasegawa T,Tango T

    更新日期:2009-01-01 00:00:00

  • An equivalence test for the comparison between a test drug and placebo in human abuse potential studies.

    abstract::Statistical methodologies for human abuse potential studies are rarely evaluated. Human abuse potential studies assess whether test drugs produce positive and negative subjective responses on abuse-related measures using volunteers with histories of recreational drug use. These studies typically have a randomized, dou...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2011.616972

    authors: Chen L,Bonson KR

    更新日期:2013-03-11 00:00:00

  • Analytical expressions for combining population pharmacokinetic parameters from different studies.

    abstract::We provide a set of formulas that allow the combination of separately performed analyses of population pharmacokinetic (PK) studies, without any further computational effort. More specifically, given the point estimates and uncertainties of two population PK analyses, the formulas provide the point estimates and uncer...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543400802071360

    authors: Dokoumetzidis A,Aarons L

    更新日期:2008-01-01 00:00:00

  • On identifying effective and superior drug combinations via Holm's procedure based on the min tests.

    abstract::In this paper I consider a problem of identifying all effective and superior drug combinations. I formulate this problem in terms of a family of hypotheses and propose a two-stage method to solve it. The first stage uses individual p-values obtained via the Min tests, whereas Holm's approach is employed in the second ...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543400802622469

    authors: Soulakova JN

    更新日期:2009-01-01 00:00:00